Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AMG 436

Small molecule · Inhibitor of Werner syndrome ATP-dependent helicase (WRN) · developed by AMGEN

Phase 1 Most advanced trial
AMGN Developer
1 Registered trials

What is AMG 436?

AMG 436 is a selective inhibitor of WRN (Werner syndrome ATP-dependent helicase) that covalently binds and inhibits the enzyme. It induces DNA damage and cell cycle arrest in tumor cells with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), and is being studied in metastatic or locally advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Werner syndrome ATP-dependent helicase (WRN)
Mechanism
Inhibitor of Werner syndrome ATP-dependent helicase (WRN)
Pathways
DNA damage, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07403721 Phase 1 Metastatic or Locally Advanced Solid Tumors With Microsatellite… Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on WRN

EIK1005 Phase 1/2

More from AMGEN

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind AMG 436

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.